Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Cardiovascular disease
•
Endocrinology
•
Lipid Disorders
Is there any difference in the cardiovascular risk reduction profile of brand name vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?
Related Questions
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
When do you recommend plasmapheresis/plasma exchange for management of severe hypertriglyceridemia?
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
What are your thoughts on the use of icosapent ethyl in clinical practice for patients with hypertriglyceridemia, and its safety profile such as increased risk of atrial fibrillation?
When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?
Would you treat an isolated elevated total cholesterol in a post-menopausal patient who is otherwise healthy and has no significant CV risk factors?
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
For patients with metabolic syndrome, is it reasonable to wait for the effect of tirzepatide therapy on their lipid profile prior to starting statin therapy?
What are the clinical indications and major limitations of lipoprotein apheresis?
